Medpace Holdings Inc.
MEDP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MEDP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$13.14B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Run Medpace Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Medpace Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 2.56 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
724
Total value held
$10.95B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,470,440 | $1.19B |
| vanguard capital management llc | 2,022,142 | $971.0M |
| aqr capital management llc | 1,353,837 | $633.6M |
| vanguard portfolio management llc | 1,121,689 | $538.6M |
| wasatch advisors lp | 773,931 | $371.6M |
| geode capital management, llc | 745,106 | $357.8M |
| state street corp | 682,229 | $327.6M |
| renaissance technologies llc | 504,668 | $242.3M |
| mawer investment management ltd. | 446,104 | $214.2M |
| d. e. shaw & co., inc. | 432,602 | $207.7M |
Showing top 10 of 724 institutional holders of Medpace Holdings Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 6.7%
- Days to cover
- 3.3
- Shares short
- 1,550,758
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MEDP short interestGovernance
Frequently asked questions
Who is the CEO of Medpace Holdings Inc.?
Dr. August James Troendle M.D. is the chief executive officer of Medpace Holdings Inc. (MEDP).
Where is Medpace Holdings Inc. headquartered?
Medpace Holdings Inc. (MEDP) is headquartered in Cincinnati, OH, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.